<DOC>
	<DOC>NCT00445939</DOC>
	<brief_summary>The purpose of this study is to demonstrate the efficacy and safety of adalimumab for the induction of clinical remission in Japanese subjects with Crohn's disease.</brief_summary>
	<brief_title>A Study of Adalimumab for the Induction of Clinical Remission in Japanese Subjects With Crohn's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Crohn's Disease Activity Index (CDAI) score of &gt;= 220 and &lt;= 450 If subjects have previously been administered infliximab, subjects who discontinued use due to a loss of response or intolerance to infliximab therapy Ulcerative colitis or indeterminate colitis History of cancer, lymphoma, leukemia or lymphoproliferative disease, active tuberculosis (TB), or Human immunodeficiency virus (HIV) Body weight is below 30 kg Surgical bowel resections within the past 6 months Females who are pregnant or breastfeeding or considering becoming pregnant during the study</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>